Insider filings
InMed Pharmaceuticals Inc. (INM)
Free on iOS and Android.
About InMed Pharmaceuticals Inc.
from the company's filings and listing, as of Oct 26, 2026- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Chief executive
- Eric A. Adams Chem.
- Employees
- 6
- Listed since
- May 5, 2014
- Market value
- $7.9M
- Price to earnings (12 mo)
- -
- Net income per share, as reported (12 mo)
- -$2.87
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 5, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q4 FY2026reported Sep 9, 2026 | -$1.43 | n/a | n/a | n/a | EPS n/aRevenue n/a |
| Q3 FY2026reported May 6, 2026 | -$0.69 | n/a | $1.3M | n/a | EPS n/aRevenue n/a |
| Q2 FY2026reported Feb 11, 2026 | -$0.51 | n/a | $1.1M | n/a | EPS n/aRevenue n/a |
| Q1 FY2026reported Nov 6, 2025 | -$0.44 | n/a | $1.3M | n/a | EPS n/aRevenue n/a |
| Q4 FY2025reported Sep 23, 2025 | $2.40 | n/a | $1.3M | $1.8M | EPS n/aRevenue miss |
| Q3 FY2025reported May 12, 2025 | -$1.94 | n/a | $1.2M | $1.5M | EPS n/aRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A figure or flag reads n/a when a number is missing, or when the figure failed our check against the company's other quarters, its own filings and its share splits, and was left out. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Nov 3, 2025| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Eric A. AdamsPresident, Chief Executive Officer and Director | $302K | $0 | $95K | $397K |
| Michael WoudenbergChief Operating Officer | $279K | $0 | $68K | $347K |
| Eric HsuSenior Vice President, Preclinical Research & Development | $268K | $0 | $56K | $324K |
| Netta JagpalChief Financial Officer | $243K | $0 | $61K | $304K |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Open-market insider trades
20 filings shown · newest filing first| Insider | Action | Shares | Price | Value | Trade date | Delay (business days) |
|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC10% owner | Bought | 1,086 | $1.32 | $1K | Oct 19, 2026filed Oct 20, 2026 | 1d |
| ADAR1 Capital Management, LLC10% owner | Bought | 1 | $1.32 | $1 | Oct 16, 2026filed Oct 20, 2026 | 2d |
| ADAR1 Capital Management, LLC10% owner | Bought | 984 | $1.32 | $1K | Oct 15, 2026filed Oct 15, 2026 | 0d |
| ADAR1 Capital Management, LLC10% owner | Bought | 8,021 | $1.33 | $11K | Oct 14, 2026filed Oct 15, 2026 | 1d |
| ADAR1 Capital Management, LLC10% owner | Bought | 564 | $1.33 | $750 | Oct 13, 2026filed Oct 15, 2026 | 2d |
| ADAR1 Capital Management, LLC10% owner | Bought | 2,256 | $1.33 | $3K | Oct 8, 2026filed Oct 8, 2026 | 0d |
| ADAR1 Capital Management, LLC10% owner | Bought | 3,046 | $1.33 | $4K | Oct 7, 2026filed Oct 8, 2026 | 1d |
| ADAR1 Capital Management, LLC10% owner | Bought | 5,601 | $1.33 | $7K | Oct 6, 2026filed Oct 8, 2026 | 2d |
| ADAR1 Capital Management, LLC10% owner | Bought | 18,182 | $1.33 | $24K | Oct 5, 2026filed Oct 5, 2026 | 0d |
| ADAR1 Capital Management, LLC10% owner | Bought | 8,307 | $1.33 | $11K | Oct 2, 2026filed Oct 5, 2026 | 1d |
| ADAR1 Capital Management, LLC10% owner | Bought | 16,431 | $1.33 | $22K | Oct 1, 2026filed Oct 5, 2026 | 2d |
| ADAR1 Capital Management, LLC10% owner | Bought | 8,340 | $1.29 | $11K | Sep 16, 2026filed Sep 16, 2026 | 0d |
| ADAR1 Capital Management, LLC10% owner | Bought | 54,256 | $1.30 | $70K | Sep 15, 2026filed Sep 16, 2026 | 1d |
| ADAR1 Capital Management, LLC10% owner | Bought | 28,505 | $1.29 | $37K | Sep 14, 2026filed Sep 16, 2026 | 2d |
| ADAR1 Capital Management, LLC10% owner | Bought | 1,000 | $1.55 | $2K | Jul 15, 2026filed Jul 17, 2026 | 2d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 5,375 | $1.55 | $8K | Jul 14, 2026filed Jul 16, 2026 | 2d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 15,150 | $1.55 | $23K | Jul 15, 2026filed Jul 16, 2026 | 1d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 21 | $1.55 | $33 | Jul 16, 2026filed Jul 16, 2026 | 0d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 600 | $1.54 | $924 | Jun 30, 2026filed Jul 2, 2026 | 2d |
| Vivo Opportunity, LLC10% owner | Bought · 2 lines | 4,344 | $1.55 | $7K | Jul 1, 2026filed Jul 2, 2026 | 1d |
One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.
Other Form 4 activity (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Andrew HullDirector | Stock award | 1,750 | Dec 19, 2025 |
| Eric A. AdamsPresident & CEO | Stock award | 35,000 | Dec 19, 2025 |
| Eric C. HsuSr. VP, Pre-Clinical Res/Dev | Stock award | 13,000 | Dec 19, 2025 |
| John Steven BatheryDirector | Stock award | 1,750 | Dec 19, 2025 |
| Michael WoudenbergChief Operating Officer | Stock award | 18,000 | Dec 19, 2025 |
| Netta JagpalChief Financial Officer | Stock award | 18,000 | Dec 19, 2025 |
| Neil A. KlompasDirector | Stock award | 1,750 | Dec 19, 2025 |
| Nicole LemerondDirector | Stock award | 1,750 | Dec 19, 2025 |
| Shane Aaron JohnsonSr VP & General Manager | Stock award | 8,500 | Dec 19, 2025 |
| Eric C. HsuSr. VP, Pre-Clinical Res/Dev | Other Form 4 entry (see filing) | 70 | Dec 15, 2025 |
| Michael WoudenbergChief Operating Officer | Other Form 4 entry (see filing) | 60 | Dec 15, 2025 |
| Eric A. AdamsPresident & CEO | Other Form 4 entry (see filing) | 250 | Dec 15, 2025 |
| Andrew HullDirector | Other Form 4 entry (see filing) | 14 | Dec 15, 2025 |
| John Steven BatheryDirector | Other Form 4 entry (see filing) | 3,500 | Oct 14, 2025 |
| Neil A. KlompasDirector | Stock award | 3,500 | Oct 17, 2025 |
| Andrew HullDirector | Other Form 4 entry (see filing) | 2 | Jan 11, 2025 |
| Andrew HullDirector | Stock award | 550 | Dec 20, 2024 |
| Bryan T. BaldasareDirector | Stock award | 550 | Dec 20, 2024 |
| Eric A. AdamsPresident & CEO | Stock award | 6,250 | Dec 20, 2024 |
| Eric C. HsuSr. VP, Pre-Clinical Res/Dev | Stock award | 2,750 | Dec 20, 2024 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Questions
Are insiders buying or selling INM?
Across the 20 most recent open-market filings shown here, 20 were purchases and 0 were sales.
How quickly are INM trades disclosed?
Insider filings on this page reached the public a median of 1 business day after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.